R&D business of what? Does that include beta bodies and Peregrine said sale or licensing ..etc and combine all this with recent events we have something brewing...
What would give better long-term potential for current shareholders and those up till Nov 27 ?
Lots of questions and if I read the complete PR by Peregrine again, there seems to be a requirement for the hiring of another firm that deals with M/A activity...quite big ones in the past so we wait : )
Like at clinicaltrials.gov, 2 sponsored trials by PPHM through NCCN.
Furthermore, look how PPHM's updated web-site has this table: Pipeline an how AstraZeneca is not removed and the 3rd NCCN trial has been mentioned to start end of this year.
PPHM wants to lisence/partner or Sell (whole or Part) of its PS-targeting but keep a node of people to coordinate effort done with NCCN, Memorial Sloan Kettering and others while letting the big boys run the end-stage clinical trials.
And then there is exosomes, biomarkers, betabodies, etc which can move forward WITHOUT Bavituximab.
Market Data 
Markets 
AI
